Rasonque Cuts Death Risk 39-68% Across RAS Subgroups in Pancreatic Cancer
RVMD has more than doubled off its 52-week low of $52.48.
Summary
Revolution Medicines presented exploratory analyses at ESMO Madrid showing Rasonque (daraxonrasib) improved overall survival versus chemotherapy across every evaluated RAS subgroup in previously treated pancreatic cancer. The risk of death fell 39% to 68% in patients with RAS mutations and 57% in those with no identified RAS mutation — notable because RAS mutations drive more than 90% of pancreatic cancers, so the benefit is not confined to the mutation-defined population. The data come from a late-stage study of 500 previously treated patients, 248 on Rasonque and 252 on chemotherapy, and also held up in harder-to-treat groups such as patients whose cancer spread within six months of earlier therapy. This broadens the commercial case for a drug the FDA approved in August and that CHMP recommended for EU approval on October 15; label expansion into combination and earlier-line settings is the next value driver, with the Phase 3 RASolute 309 combination trial already dosing.
At the time of this announcement, RVMD was trading at $189.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.2B. The 52-week trading range was $52.48 to $224.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.